Metformin enhances insulin sensitivity by suppressing hepatic gluconeogenesis and improving peripheral glucose uptake, reducing hyperinsulinemia and downstream ovarian androgen production ( The extent of weight loss observed with GLP-1 receptor agonists, especially in combination with metformin, is clinically relevant in the context of PCOS, a condition in which insulin resistance, central obesity, and metabolic dysfunction contribute to eventual infertility and long-term cardiometabolic risk ( Given the heterogeneity of PCOS phenotypes, a personalized, combination-based therapeutic approach may optimize outcomes beyond a uniform treatment model
Is there teaching on healthy habits, or just medication
GLP patches are adhesive wellness products marketed for appetite control or weight loss by borrowing the GLP-1 name
Long-term cardiovascular outcome data are still being collected through additional trials
9 For employers and health plans this volatility and shift in government pricing benchmarks may eventually cascade into future contract negotiations and formulary structures